Iron Triangle Partners LP Has $34.09 Million Stake in Teva Pharmaceutical Industries Ltd. $TEVA

Iron Triangle Partners LP lifted its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 0.8% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,217,730 shares of the company’s stock after acquiring an additional 17,694 shares during the quarter. Teva Pharmaceutical Industries accounts for about 5.4% of Iron Triangle Partners LP’s investment portfolio, making the stock its 4th largest holding. Iron Triangle Partners LP owned 0.20% of Teva Pharmaceutical Industries worth $34,087,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Jump Financial LLC grew its stake in shares of Teva Pharmaceutical Industries by 172.1% in the first quarter. Jump Financial LLC now owns 1,325,526 shares of the company’s stock worth $20,373,000 after acquiring an additional 838,423 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its holdings in shares of Teva Pharmaceutical Industries by 5.7% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,504,007 shares of the company’s stock worth $38,487,000 after buying an additional 134,705 shares during the last quarter. Financial Sense Advisors Inc. boosted its holdings in shares of Teva Pharmaceutical Industries by 63.5% in the first quarter. Financial Sense Advisors Inc. now owns 405,421 shares of the company’s stock worth $6,231,000 after buying an additional 157,421 shares during the last quarter. King Wealth Management Group boosted its holdings in shares of Teva Pharmaceutical Industries by 1,106.9% in the first quarter. King Wealth Management Group now owns 175,000 shares of the company’s stock worth $2,690,000 after buying an additional 160,500 shares during the last quarter. Finally, GAMMA Investing LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 804.7% in the first quarter. GAMMA Investing LLC now owns 67,474 shares of the company’s stock worth $1,037,000 after buying an additional 60,016 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.

Insider Transactions at Teva Pharmaceutical Industries

In other news, insider Eric A. Hughes sold 52,742 shares of the business’s stock in a transaction on Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $799,568.72. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Placid Jover sold 6,053 shares of the business’s stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $91,763.48. Following the completion of the transaction, the insider directly owned 6,774 shares in the company, valued at $102,693.84. This trade represents a 47.19% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 65,001 shares of company stock valued at $996,958. 0.49% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have weighed in on TEVA. Truist Financial began coverage on shares of Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They set a “buy” rating and a $25.00 price target on the stock. UBS Group lowered their price target on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a “buy” rating on the stock in a report on Thursday, June 26th. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $21.00 to $23.00 in a report on Monday, May 12th. The Goldman Sachs Group began coverage on shares of Teva Pharmaceutical Industries in a report on Friday, June 6th. They set a “buy” rating and a $24.00 price target on the stock. Finally, Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Saturday, July 26th. Two investment analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the company’s stock. According to MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of “Buy” and an average price target of $24.71.

Teva Pharmaceutical Industries Price Performance

TEVA stock opened at $18.03 on Friday. Teva Pharmaceutical Industries Ltd. has a one year low of $12.47 and a one year high of $22.80. The company’s fifty day moving average price is $16.83 and its 200-day moving average price is $16.31. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06. The company has a market capitalization of $20.67 billion, a PE ratio of -112.66, a price-to-earnings-growth ratio of 1.07 and a beta of 0.62.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.64 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The firm had revenue of $4.18 billion for the quarter, compared to the consensus estimate of $4.34 billion. During the same quarter in the previous year, the firm earned $0.61 earnings per share. The company’s quarterly revenue was up .3% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. On average, equities analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.